Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Barclays Capital Global Healthcare Conference 2011
17 slides from Teva Pharmaceutical Industries's conference presentation, Mar 16, 2011
Slide 1: Barclays Capital Global Healthcare Conference
Barclays Capital Global Healthcare Conference Jon Congleton, SVP & General Manager, Teva Neuroscience March 16, 2011 We make quality healthcare accessible around the world 1
Slide 2: Forward-looking statements
Forward-looking statements TODAY’S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE OUR FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIF
Slide 3: Teva and Neuroscience
Teva and Neuroscience 1970’s began work with coploymer-1 1995: Joint venture between Teva and Marion Merrell Dow established. 1997: Launched Copaxone in the U.S. 2001: Teva buys out JV. 2006: Launched Azilect in the U.S. Staff: “Big Pharma” talent throughout and deep knowledge of the M
Slide 4: COPAXONE
COPAXONE We make quality healthcare accessible around the world 4
Slide 5: MS Market Space in the U.S.
MS Market Space in the U.S. ~10,000 Treating Neuros Managed care rebates relatively constant Co-insurance 472,000 Share Payor Consolidation Total US MS Patients (est) “Donut Hole” ~25,000 Managed Medicaid Betaseron Patients Location 80,000 226,000 ~63,000 RRMS RRMS Avonex ~60,000 CIS CIS Patients Sp
Slide 6: MS Situation Analysis
MS Situation Analysis Competitive pressure in MS Market is Increasing Branded competitors may double over five years COPAXONE strengths to defend leadership position include: Teva reputation, Patient database asset, Established access and support systems, Proven long-term efficacy and safety w
Slide 7: IMS TRx Market Share 2010
IMS TRx Market Share 2010 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% Jan-10 Feb Mar Apr May June July Aug Sept Oct Nov Dec Jan '11 Avonex COPAXONE Betaseron Rebif Tysabri Extavia Gilenya IMS Monthly MS Topline Report, January 2011 We make quality healthcare accessible around the world 7
Slide 8: IMS TRx Volume
IMS TRx MS Volume 2010 vs 2009 IMS TRx Volume Difference 2010 vs 2009 40,000 30,000 20,000 IMS TRx Volume 10,000 - Avonex COPAXONE Betaseron Rebif Tysabri Extavia Gilenya (10,000) (20,000) (30,000) We make quality healthcare accessible around the world 8
Slide 9: Evolving MS Market Dynamics
Evolving MS Market Dynamics COPAXONE and Laquinimod will Compete in a More Complex Environment Cladribine ??? Betaseron® Tysabri® (IFNβ-1b) (natalizumab) ® Campath® Avonex Extavia® (alemtuzumab) (IFNβ-1a) (IFNβ-1b) COPAXONE® Laquinimod (glatiramer acetate injection) Fingolimod (FTY720) Fumarate Nova
Slide 10: COPAXONE Development and Investment
COPAXONE Development and Investment GALA Three times a week Copaxone Rapid trial enrollment Anticipate closure of trial and data mid-2012 Potential market entry mid to late 2013 Copaxone 0.5ml Feedback received from FDA on initial filing Need for clinical data requested from the agency
Slide 11: Laquinimod
Laquinimod We make quality healthcare accessible around the world 11
Slide 12: Laquinimod Market Opportunity
Laquinimod Market Opportunity 472,000 Total US MS Patients (est) ~25,000 Betaseron Patients Value of 27,000 Naïve 80,000 226,000 ~63,000 $2B if RRMS RRMS Avonex IFN conversion 53,000 Previous CIS CIS Patients treated Copaxone at risk 222,000 of DC 250,000 ~100,000 101,000 Not on 17,000 Treated COPAX
Slide 13: Laquinimod
Laquinimod Laquinimod is a novel and promising oral, once-daily, small molecule immunomodulator (SMI) with a differentiated mechanism of action In ALLEGRO, laquinimod achieved primary and secondary endpoints, demonstrating a significant positive impact on disease activity, neurodegeneration and
Slide 14: Laquinimod Timeline
Laquinimod Timeline FDA Submission Of Laquinimod ALLEGRO Trial BRAVO Trial FDA Approval Announcement Announcement Potential ECTRIMS ALLEGRO Presentations Laquinimod Data Results AAN ALLEGRO & AAN 2012 2011 BRAVO Q4 ‘10 Q1 ‘11 Q2 ‘11 Q3 ‘11 Q4 ‘11 Q1 ‘12 Q2 ‘12 We make quality healthcare accessible a
Slide 15: Azilect
Azilect We make quality healthcare accessible around the world 15
Slide 16: Parkinson's Situation Analysis
Parkinson’s Situation Analysis Market Conditions Top attributes for selecting a PD therapy are: Slows progression , Effective for motor symptoms, Improves ADL, Safe & Convenient Competitive PD brands promotional presence has diminished PD Rx volume is 85% generic Mirapex, Requip, Stalevo a
Slide 17: Azilect
Azilect Indicated as initial therapy and as adjunctive at first signs of wearing “off” with other PD therapies Extensive clinical profile Potential for disease modification as seen in TEMPO and ADAGIO Safe, well tolerated and convenient Promoted Brand PD Therapies 35,000 30,000 25,000 Mirape
Teva Pharmaceutical Industries — Barclays Capital Global Healthcare Conference 2011 on 6ix